Scott Reents
EVP & CFO at AbbVie
In immunology, we now expect SKYRIZI global revenues of $17,100,000,000 an increase of $600,000,000 reflecting continued share gains in psoriasis and IBD. And US HUMIRA revenues of $3,000,000,000 a decrease of $500,000,000 reflecting biosimilar competition. In neuroscience, we now expect global sales of $10,500,000,000 an increase of 300,000,000 This includes a $100,000,000 increase for vial of reflecting strong international uptake with the remaining $200,000,000 increase split relatively evenly across Vraylar, Botox Therapeutic, and the total oral CGRP portfolio. And in oncology, we now expect IMBRUVICA global revenues of 2,900,000,000.0, an increase of $100,000,000 reflecting higher persistency rates for existing patients. And VENCLEXTA global sales of $2,800,000,000 an increase of $100,000,000 reflecting continued strong demand in CLL.